Propylthiouracil
Audience: Endocrine healthcare professionals, Pharmacists, Pediatricians
FDA notified healthcare professionals of the risk of serious liver injury, including liver failure and death, with the use of propylthiouracil in adult and pediatric patients. Reports to FDA's Adverse Event Reporting System (AERS) suggest there is an increased risk of hepatotoxicity with proplythiouracil when compared to methimazole. FDA has identified 32 (AERS) cases (22 adult and 10 pediatric) of serious liver injury associated with proplythiouracil use. Although both proplythiouracil and methimazole are indicated for the treatment of hyperthyroidism due to Graves' disease, healthcare professionals should carefully consider which drug to initiate in a patient recently diagnosed with Graves' disease. Physicians should closely monitor patients on proplythiouracil therapy for symptoms and signs of liver injury, especially during the first six months after initiation of therapy. Proplythiouracil should not be used in pediatric patients unless the patient is allergic to or intolerant of methimazole, and there are no other treatment options available.
[06/03/2009 - Healthcare Professional Sheet - FDA]
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.